CN110317867A - Application of the TARS as the molecular marker of diagnosis Male Osteoporosis - Google Patents
Application of the TARS as the molecular marker of diagnosis Male Osteoporosis Download PDFInfo
- Publication number
- CN110317867A CN110317867A CN201910626648.2A CN201910626648A CN110317867A CN 110317867 A CN110317867 A CN 110317867A CN 201910626648 A CN201910626648 A CN 201910626648A CN 110317867 A CN110317867 A CN 110317867A
- Authority
- CN
- China
- Prior art keywords
- tars
- reagent
- gene
- osteoporosis
- male osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides purposes of the TARS as the molecular marker of diagnosis Male Osteoporosis.Of the invention research shows that TARS is in normal healthy controls and expression in Male Osteoporosis blood samples of patients, there are significant differences, think that TARS can be used as the molecular marker of diagnosis Male Osteoporosis accordingly.The product that can be used for early diagnosing Male Osteoporosis is developed according to the studies above achievement, the product recall rate is good, is suitble in clinical expansion.
Description
Technical field
The invention belongs to fields of biomedicine, are related to the application of TARS, and in particular to TARS is dredged as diagnosis male's sclerotin
The molecular marker of loose disease is answered.
Background technique
Osteoporosis is one group of osteopathy caused by many reasons, and bone tissue has normal calcification, calcium salt and matrix in just
Normal ratio, the metabolic bone disease with the characteristics of the reduction of unit volume inner bone tissues amount become.In most osteoporosises, bone tissue
It reduces caused by increasing mainly due to bone absorption.By skeleton pain, be easy to fracture characterized by.
Osteoporosis has been classified as the disease for being only second to the second largest harm human health of cardiovascular disease by the World Health Organization
Disease.Promote " 2013 Chinese osteoporotic fractures prevent and treat blue book " display of the newest publication of foundation according to China's Healthy, sclerotin is dredged
Pine fracture is a kind of fragility fractures, i.e., by low energy wound, that is, generable bone in by minor trauma or daily routines
Folding.The common site of osteoporotic fracture is vertebra, hipbone and distal forearm.China 50 years old or more about 69,440,000 people of crowd suffers from
Osteoporosis, about 2.1 hundred million people's bone amounts are relatively low.
It is far from enough for the degree of concern and the depth of investigation of osteoporosis in aged males in China.But old male
Property osteoporosis harm and be no less than women, the illness rate and case fatality rate of male's Hip Fracture be apparently higher than women.
Studies at home and abroad show that the risk factor of Male Osteoporosis includes:
(1) age growth is an independent hazard factor of Male Osteoporosis.Shadow of the age for bone metabolism
It rings and may include relatively active to bone resorption, and osteogenic action is suppressed, and bone resorption is caused to be greater than bon e formation.At the same time,
With age, kidney l α hydroxylase activity declines, 1,25 (OH) of activity2D3It reduces, intestinal calcium absorption decline, blood calcium reduces, draws
Secondary hyperparathyroidism is played, bone loss is caused.
(2) body mass index (body mass index, BMI) BMI is influence osteoporosis in aged males illness rate one
A important indicator.One important indicator of Male Osteoporosis illness rate.Studies have shown that BMI is less than 20-25kg/m2People
Group, which suffers from osteoporosis possibility, will increase, and be greater than 25kg/m with BMI2Crowd compare, BMI 15-20kg/m2Trouble
A possibility that person's marrow is fractured will increase.In addition studies have found that, the every increase 1kg/m of BMI2Measure neck of femur, marrow and lumbar vertebrae
BMD increase separately 0.1SD, 0.11SD and 0.09SD.BMI increase can cause the mechanical load of bone to increase, and stimulate bone shape
At and reduce bone resorption.
(3) endocrine hormone influence androgen levels reduce be osteoporosis in aged males a significant risk because
Element.There are androgen receptor on osteocyte, androgen directly acts on these receptors to promote osteoblast to strengthen bone.It is old
One hypophysis of male's hypothalamus, one gonad index lowers, hypo-orchidia, testosterone levels decline, and sex hormone binding globulin
Level increases, and causes the osteogenic action of osteoblast to weaken, bone density is caused to decline.
(4) inherent cause inherent cause is occupied an important position in the morbidity of Male Osteoporosis.Osteoporosis at present
Genetic research mainly includes two broad aspect of Population Genetics and molecular genetics, is directed to ethnic group, family and gene pleiomorphism respectively
It is studied.The most significant determinant of Peak Bone Mass is inherent cause, influences that 60%-80% may be accounted for.
(5) calcium agent and vitamin D in the composition proportion especially food of trophic level patient chronic dietary habit and food
Content certain effect is also played to the morbidity of osteoporosis.Meta analysis shows supplement calcium and vitamine D3 crowd,
BMD is increased, and the risk fractured reduces.Calcium agent can reduce bone amount loss, prevent vertebral fracture, and non-to preventing
Vertebral fracture may also be helpful.
In addition, living habit include movement, smoking, heavy drinking be also Male Osteoporosis important risk factor.
Diagnosis of osteoporosis it may first have to carry out the measurement of bone density.Bone density is actually to indicate the health of bone
Degree, or the degree of aging of bone is indicated on the contrary.Commonly detection means includes:
X ray photograph method: usage history is earliest, but due to there is radioactivity, test result is not energetic, is gradually taken
Generation.
Single photon analyzer: expense is low, conveniently, amount of radiation it is small and safe.But because that cannot survey bone of body and cannot distinguish
Cortex bone, cancellous bone, soft tissue etc. and be restricted, be gradually substituted.
Quantitative Ultrasound Methods: it is cheap, conveniently, again "dead" damage.It is suitble to the bone-shaped state census operations of each age group crowd.
Bone density can not only be detected, moreover it is possible to understand bone quality can reactive bone micro-structure and elasticity.But it is currently only used for calcaneum, shin
Bone and phalanges not can be carried out the detection of Whole Body Bone Scanning bone.
Dual energy X-ray absorptiometry: being current optimal measuring method, be the goldstandard of Diagnosis of osteoporosis, logical both at home and abroad
With can survey each position bone of whole body, can also survey soft tissue thickness, but the number of devices is less and expensive, therefore for bone
Financial burden is big for the diagnosis of matter osteoporosis patient.Examining for a kind of high sensibility, accuracy height and reasonable price is found thus
The method of disconnected osteoporosis is a problem to be solved.
Summary of the invention
In order to overcome the shortage of prior art, the purpose of the present invention is to provide a kind of genes for Diagnosis of osteoporosis
Marker.QPCR of the present invention is experiments have shown that expression of the TARS in Male Osteoporosis blood samples of patients is apparently higher than health
Level in male's blood, therefore can be using TARS as the molecular marker of diagnosis Male Osteoporosis.
In order to test above-mentioned purpose, present invention employs following technical solutions:
The present invention provides the reagents of detection gene expression in the application for preparing diagnosis of osteoporosis product；The gene
It is TARS.
Further, the reagent including the use of SYBR Green, TaqMan probe, molecular beacon, double cross probe or is answered
The PCR amplification primer used when closing probe in detecting TARS expression quantity.
In specific embodiments of the present invention, the primer sequence is as shown in SEQ ID NO.1 and SEQ ID NO.2.
The present invention provides a kind of product for diagnosis of osteoporosis, the product includes detection TARS expression
Reagent.
Further, the reagent includes SYBR Green, TaqMan probe, molecular beacon, double cross probe or compound spy
Needle detects the PCR amplification primer used when TARS expression quantity.
In specific embodiments of the present invention, the primer sequence is as shown in SEQ ID NO.1 and SEQ ID NO.2.
Further, mentioned-above product includes but is not limited to chip, kit, test paper or high-flux sequence platform；It is high
Flux microarray dataset is a kind of tool of special Diagnosis of osteoporosis, with the development of high throughput sequencing technologies, to one
The building of the rna expression spectrum of people will become very easily work.By the rna expression for comparing Disease and normal population
Spectrum, the exception for being easy to analyze which RNA are related to disease.Therefore, TARS abnormal expression and bone are known in high-flux sequence
Matter osteoporosis correlation also belongs to the purposes of TARS, equally within protection scope of the present invention.
The kit includes the reagent for detecting TARS expression quantity, and the reagent includes in conjunction with TARS or its DNA sequence dna
Nucleic acid, the nucleic acid include SYBR Green, TaqMan probe, molecular beacon, double cross probe or combined probe detection
The PCR amplification primer used when TARS expression quantity.
The chip includes the reagent for detecting TARS expression quantity, and the reagent includes in conjunction with TARS or its DNA sequence dna
Nucleic acid, the nucleic acid include the probe for being able to detect TARS expression quantity.
The test paper includes the reagent for detecting TARS expression quantity, and the reagent includes in conjunction with TARS or its DNA sequence dna
Nucleic acid, the nucleic acid include the probe for being able to detect TARS expression quantity.
The present invention provides a kind of for treating the pharmaceutical composition of osteoporosis, and described pharmaceutical composition includes TARS
The inhibitor of gene.
Further, the inhibitor is unrestricted, as long as can inhibit TARS expression or inhibit TARS function living
Property.
The inhibitor includes siRNA, shRNA, suppressive miRNA or suppressive targeting small molecule compound.
Pharmaceutical composition of the invention can be used as medicine and be administered alone or apply together with other medicines.It can be with this hair
The other medicines that bright pharmaceutical composition is applied together are unrestricted, as long as it does not damage therapeutic or preventative medicine of the invention
The effect of compositions.
Pharmaceutical composition of the invention can be prepared into various dosage forms as needed.Including but not limited to, percutaneous, mucous membrane, nose,
Buccal, the sublingual or oral tablet used, solution, granule, patch, paste, capsule, aerosol or suppository.
The administration method of pharmaceutical composition of the invention is unrestricted, as long as it can play desired therapeutic effect or prevention
Effect, including but not limited to intravenously, in peritonaeum, intraocularly, intra-arterial, intrapulmonary is taken orally, in vesicle, intramuscular, and tracheae
Interior, subcutaneous, local by pleura by skin, sucking, by mucous membrane, skin, stomach is intra-articular, intra-ventricle, directly
Intestines, vagina, in skull, in urethra, in liver, in tumor.In some cases, it can systematically be administered.It is office in some cases
Portion it is administered.
The dosage of pharmaceutical composition of the invention is unrestricted, as long as obtaining desired therapeutic effect or preventive effect i.e.
Can, appropriate determination can be carried out according to symptom, gender, age etc..Therapeutic agent composition of the invention or prophylactic agent combination
The dosage of object, which can be used, for example determines the therapeutic effect of disease or preventive effect as index.
The present invention also provides application of the TARS gene in the drug of preparation treatment osteoporosis.The drug includes
Inhibit the reagent of TARS gene.The reagent is unrestricted, as long as can inhibit TARS expression or inhibit TARS function
Activity.
The present invention also provides application of the mentioned-above inhibitor in the drug of preparation treatment osteoporosis.
The present invention also provides a kind of methods of Diagnosis of osteoporosis, and described method includes following steps:
(1) sample of subject is obtained；
(2) expression of TARS in Samples subjects is detected；
(3) it associates whether by the expression of the TARS measured with the illness of subject.
(4) compared with normal control, the expression of TARS is significantly increased, then the subject is judged with osteoporosis
Disease judges that risk of the subject with osteoporosis is high.
The present invention also provides a kind for the treatment of method of osteoporosis, the method includes inhibit TARS expression quantity or
Inhibit the adjusting activity of TARS.
In the context of the present invention, " Diagnosis of osteoporosis " includes judging whether subject has suffered from osteoporosis
Disease judges that subject whether there is the risk with osteoporosis.
" treatment " used herein is covered treatment-related in such as mankind of the mammal with related disease or illness
Disease or morbid state, and include:
(1) prevent disease or morbid state occurs in mammals, especially when the mammal is susceptible in the disease
Diseased state, but when being not yet diagnosed with this morbid state；
(2) inhibit disease or morbid state, that is, prevent its generation；Or
(3) alleviate disease or morbid state, even if disease or morbid state subside.
Term " treatment " is usually directed to treatment mankind or animal (for example, being applied by animal doctor), wherein can reach certain pre-
The therapeutic effect of phase, for example, inhibiting the development (including reduce development speed, stop development) of illness, improving illness and healing
Illness.It further include the treatment as precautionary measures (such as prevention).To not yet development be illness but have development be the illness endanger
The purposes of the patient of danger, is also included in term " treatment ".
In the context of the present invention, " TARS gene " includes any functional equivalent of TARS gene and TARS gene
Polynucleotides.TARS gene (Chromosome 5, NC_000005.10 (33440696..33468091)) sequence can be in state
It is inquired in the public GenBank GeneBank in border.
The advantages of the present invention:
Present invention finds a kind of molecular markers of Diagnosis of osteoporosis, can be in sclerotin using the molecular marker
Osteoporosis occur early stage can be used as judging, improve patient's cure rate.
Detailed description of the invention
Fig. 1 shows the statistical chart of the differential expression situation using QPCR detection TARS.
Specific embodiment
The present invention is described in further detail with reference to the accompanying drawings and examples.Following embodiment is merely to illustrate this
It invents rather than limits the scope of the invention.Test method without specific conditions in embodiment, usually according to conventional strip
Part, such as Sambrook et al., molecular cloning: laboratory manual (New York:Cold Spring HarborLaboratory
Press, 1989) condition described in, or according to the normal condition proposed by manufacturer.
Embodiment 1QPCR detects difference expression gene
One, sample collection
30 Male Osteoporosis patients are chosen, inclusion criteria: the T < -2.5 of dual-energy x-ray absorptiometry* bone density；T<-2.5
And with the past fragility fractures history；The normal person of Liver and kidney function.Exclusion criteria: osteosporosis resistant medicament person was 1. previously used；②
There are the endocrine system diseases such as diabetes, thyroid gland or disease of parathyroid glands, adrenal gland and sexual gland；3. secondary osteoporosis.It is flat
Equal 78 years old age.The peripheral blood of above-mentioned patient is extracted as laboratory sample, is collected simultaneously the peripheral blood conduct pair of 30 normal persons
Product in the same old way.
Two, it is verified in mRNA level in-site
1, Total RNAs extraction
Blood is extracted using the efficient blood total RNA extraction reagent box of the RNAprep Pure of Tiangeng company (article No.: DP443)
Total serum IgE operates to specifications, and substantially steps are as follows:
(1) 10 × red blood cell of proper volume the dilution of erythrocyte cracked liquid: is chosen according to the volume of processing blood sample
Lysate H (such as blood sample volume to be processed is 200 μ l, then takes 140 10 × erythrocyte cracked liquid H of μ l), uses RNase-
Free ddH2O is diluted to 1 × erythrocyte cracked liquid H.
(2) add 5 times of 1 × erythrocyte cracked liquid of volume H (suitable clean pipe need to be provided for oneself) into 1 volume human whole blood.
Note: for the optimal mixed effect of acquisition, the mixeding liquid volume of blood and 1 × erythrocyte cracked liquid H are not to be exceeded
The 3/4 of pipe volume.If the leucocyte content in blood is higher, the use volume of blood can be scaled down, in step 6
The use volume of 1 × erythrocyte cracked liquid H will also adjust accordingly.
(3) it is incubated for 10-15min on ice, vortex oscillation mixes 2 times during incubation.
Note: solution will become translucent during incubation, show erythrocyte splitting.If necessary,
Incubation time can extend to 20min.
(4) 4 DEG C of 2,100rpm (~400 × g) are centrifuged 10min, and supernatant is completely removed.
Note: leucocyte may will form bead after centrifugation, it is ensured that completely remove supernatant, the presence of trace red blood cell, meeting
Leucocyte bead is presented red, and the phenomenon can disappear in subsequent rinse step.
(5) 1 × erythrocyte cracked liquid H is added into leukocyte cell pellet, and (volume of addition 1 × erythrocyte cracked liquid H is the 1st
2 times of whole blood dosage in step), cell is resuspended.
(6) 4 DEG C, 2,100rpm (~400 × g) are centrifuged 10min, and supernatant is completely removed.
Note: if supernatant removal will not exclusively will affect the combination of cracking and subsequent RNA and film, leading to last RNA
Yield reduces.
(7) lysate RLH (beta -mercaptoethanol please be added before use) is added into leukocyte cell pellet, specific dosage is under
Table 1 carries out, and is vortexed or is mixed using pipettor.
Note: it if blood is not the whole blood of Healthy People, needs to determine required cracking according to the quantity of blood middle leukocytes
The volume of liquid RLH, cell should crack completely at this time, and blocky cell precipitation disappears.
1 lysate of table uses scale
(8) solution is transferred in Filter column CS (Filter column CS is placed in collecting pipe), 12,000rpm (~13,400 ×
G) it is centrifuged 2min, discards Filter column CS, collects filtrate.
Note: for the formation for avoiding aerosol, pipettor being please adjusted to >=750 μ l to guarantee all solution disposably
It is transferred on Filter column, if cell is too many, it will the sticky phenomenon of lysate occur, cause to be difficult to the case where drawing.
(9) 1 times of 70% ethyl alcohol of volume (usually 350 μ l or 600 μ l) is added into filtrate, mixing (may go out at this time
Now precipitate), obtained solution and precipitating is transferred in adsorption column CR4 (adsorption column CR4 is put into collecting pipe) together, and 12,000rpm
(~13,400 × g) is centrifuged 30-60sec, outwells the waste liquid in collecting pipe, adsorption column CR4 is put back in collecting pipe.
Note: RNase-Free ddH2O please be use when preparing 70% ethyl alcohol, it, please be corresponding if filtrate volume is lost
Reduce by 70% ethanol consumption.When solution and precipitating are transferred to adsorption column CR4, volume is greater than absorption column capacity, can be in two times
It completes.
(10) if digested without DNase I, 700 μ l protein liquid removal RW1H can directly be added into adsorption column CR4
(please first check whether before use and ethyl alcohol has been added), 12,000rpm (~13,400 × g) are centrifuged 30-60sec, outwell collecting pipe
In waste liquid, directly progress step 14.
DNase I digestion: 350 μ l protein liquid removal RW1H, 12,000rpm (~13,400 × g) are added into adsorption column CR4
It is centrifuged 30-60sec, the waste liquid in collecting pipe is outwelled, adsorption column CR4 is put back in collecting pipe.
(11) preparation of DNase I working solution: 10 μ l DNase I storing liquids is taken to be put into new RNase-Free centrifuge tube
In, 70 μ lRDD solution are added, it is soft to mix.
(12) the DNase I working solution of 80 μ l is added to the center adsorption column CR4, is placed at room temperature for 15min.
(13) 350 μ l protein liquid removal RW1H, 12,000rpm (~13,400 × g) are added into adsorption column CR4 and are centrifuged 30-
60sec outwells the waste liquid in collecting pipe, and adsorption column CR4 is put back in collecting pipe.
(14) 500 μ l rinsing liquid RW (please first check whether before use and ethyl alcohol has been added), room temperature are added into adsorption column CR4
2min is stood, 12,000rpm (~13,400 × g) are centrifuged 30-60sec, outwell the waste liquid in collecting pipe, adsorption column CR4 is put
It recycles in collector.
(15) step 14 is repeated.
(16) 12,000rpm (~13,400 × g) are centrifuged 2min, outwell waste liquid.Adsorption column CR4 is placed in and is placed at room temperature for number
Minute, thoroughly to dry rinsing liquid remaining in adsorbent material.
Note: adsorption column CR4 being placed at room temperature for a moment after centrifugation, sufficiently to dry.It, may if there is rinsing liquid remains
It will affect subsequent reverse transcription, the experiment such as fluorescent quantitation.
(17) adsorption column CR4 is transferred in a new RNase-Free centrifuge tube, 30-50 μ l RNase-Free is added
ddH2O is placed at room temperature for 2min, and 12,000rpm (~13,400 × g) are centrifuged 2min, obtain RNA solution.
Note: elution buffer volume should not be less than 30 μ l, the too small influence recovery efficiency of volume.RNA solution is please in -70 DEG C
It saves.
2, reverse transcription reaction
Total serum IgE is reversed using the RNA that PrimeScript RT reagent Kit (TAKARA company) purifies 1000ng
Record synthesis cDNA.
1) removal genomic DNA reaction, by the following ingredient in table 2 in preparing reaction mixture on ice.
Table 2 removes genomic DNA reaction system
| Reagent | Usage amount |
| 5*gDNA Eraser Buffer | 2.0μL |
| gDNA Eraser | 1.0μL |
| Total serum IgE | 1μL |
| Without RNase water | To 10 μ L |
2) it is reacted in PCR instrument
42℃2min；
4 DEG C of preservations.
3) reverse transcription reaction
Reaction solution preparation carries out on ice, and ingredient is as shown in table 3.In order to guarantee the accuracy of reaction solution preparation, carry out each
When item reaction, Master Mix first should be prepared by the amount of stoichiometric number+2, then dispense 10 μ L again into each reaction tube.It is soft mixed
Reverse transcription reaction is carried out after even immediately.
3 reverse transcription reaction system of table
| Reagent | Usage amount |
| Back reaction solution | 10μL |
| PrimeScript RT Enzyme Mix I | 1.0μL |
| RT Primer Mix | 1.0μL |
| 5*PrimeScript Buffer 2(for Real Time) | 4.0μL |
| RNase Free dH2O | 4.0μL |
| Always | 20μL |
4) it is reacted in PCR instrument:
37℃15min；
85℃5sec；
4 DEG C of preservations.
3, real-time quantitative reverse transcription polymerase chain reaction (QPCR)
1) SYBR Premix Ex Taq Kit (TAKARA company) is used, (ratio is such as 10 μ L PCR reaction systems of configuration
Shown in table 4), other reagents in addition to cDNA are premixed, each sample individual gene makes multiple holes in triplicate, sequentially adds
In 96 orifice plates, with ddH2O is as negative control.
4 QPCR reaction system of table
Primer sequence is as follows:
TARS
Forward primer: 5 '-CAACCTGTGATGAATATG-3 ' (SEQ ID NO.1),
Reverse primer: 5 '-TTATACTGTGCTAACTGT-3 ' (SEQ ID NO.2)；
GAPDH
Forward primer: 5 '-GTGGACCTGACCTGCCGTCT-3 ' (SEQ ID NO.3),
Reverse primer: 5 '-GGAGGAGTGGGTGTCGCTGT-3 ' (SEQ ID NO.4).
2) program is arranged:
Initial denaturation Cycle:1
95 DEG C 35 seconds；
95 DEG C 5 seconds+54 DEG C 34 seconds, totally 45 circulation.
3) the Ct value of each sample is obtained, the relative expression quantity of all target genes is calculated by (2- △ △ Ct), with same group
Reference gene GAPDH is respectively as control.
4, result
As a result as shown in Figure 1, compared with 30 normal control population's average levels, in 30 Male Osteoporosis patients
The mRNA level in-site of TARS gene obviously raises in all patients blood, and difference has statistical significance (P < 0.05).
The preparation of 2 Male Osteoporosis diagnostic kit of embodiment
According to the correlation of TARS gene and Male Osteoporosis, can by detect the expression of TARS gene come
Male Osteoporosis is diagnosed, osteoporosis is diagnosed based on detection TARS gene expression the present invention provides a kind of accordingly
The kit of disease, the component in the diagnostic kit are as follows: SYBR Green polymerase chain reaction system；Expand TARS gene
With the primer pair of GAPDH gene.The forward primer sequence for expanding TARS gene is 5 '-CAACCTGTGATGAATATG-3 ', reversely
Primer sequence is 5 '-TTATACTGTGCTAACTGT-3 '；The forward primer sequence for expanding GAPDH is 5 '-
GTGGACCTGACCTGCCGTCT-3 ', reverse primer sequences 5 '-GGAGGAGTGGGTGTCGCTGT-3 '.SYBR Green is poly-
Polymerase chain reaction system includes PCR buffer, dNTPs, SYBR Green fluorescent dye.PCR buffer components are as follows: 25mM
KCL, 2.5mM MgCL2、200mM(NH4)2SO4。
The explanation of above-described embodiment is only intended to understand method and its core concept of the invention.It should be pointed out that for this
For the those of ordinary skill in field, without departing from the principle of the present invention, several improvement can also be carried out to the present invention
And modification, these improvement and modification will also be fallen into the protection scope of the claims in the present invention.
Sequence table
<110>People's Hospital of Deyang City
<120>application of the TARS as the molecular marker of diagnosis Male Osteoporosis
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 18
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
caacctgtga tgaatatg 18
<210> 2
<211> 18
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
ttatactgtg ctaactgt 18
<210> 3
<211> 20
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
gtggacctga cctgccgtct 20
<210> 4
<211> 20
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 4
ggaggagtgg gtgtcgctgt 20
Claims (10)
1. detecting application of the reagent of gene expression in the diagnostic products for preparing Male Osteoporosis；The gene is
TARS。
2. application according to claim 1, which is characterized in that the reagent is visited including the use of SYBR Green, TaqMan
Needle, molecular beacon, double cross probe or combined probe detect the PCR amplification primer used when the gene expression amount.
3. application according to claim 2, which is characterized in that the primer sequence such as SEQ ID NO.1 and SEQ ID
Shown in NO.2.
4. a kind of product for Male Osteoporosis diagnosis, which is characterized in that the product includes detection claim 1 institute
The reagent for the gene expression stated.
5. product according to claim 4, which is characterized in that the reagent includes SYBR Green, TaqMan probe, divides
Sub- beacon, double cross probe or combined probe detect the PCR amplification primer used when the gene expression amount.
6. product according to claim 5, which is characterized in that the primer sequence such as SEQ ID NO.1 and SEQ ID
Shown in NO.2.
7. a kind of for treating the pharmaceutical composition of Male Osteoporosis, which is characterized in that described pharmaceutical composition includes power
Benefit require 1 described in gene inhibitor.
8. product according to claim 7, which is characterized in that the inhibitor includes inhibiting the gene expression dose
Reagent, or inhibit the active reagent of gene function.
9. application of the gene described in claim 1 in the drug of preparation treatment Male Osteoporosis.
10. application according to claim 9, which is characterized in that the drug includes the reagent for inhibiting the gene.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910626648.2A CN110317867A (en) | 2019-07-11 | 2019-07-11 | Application of the TARS as the molecular marker of diagnosis Male Osteoporosis |
| CN201911029476.7A CN110564845B (en) | 2019-07-11 | 2019-10-28 | Application of TARS (total amyloid receptor) as molecular marker for diagnosing male osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910626648.2A CN110317867A (en) | 2019-07-11 | 2019-07-11 | Application of the TARS as the molecular marker of diagnosis Male Osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110317867A true CN110317867A (en) | 2019-10-11 |
Family
ID=68122032
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910626648.2A Pending CN110317867A (en) | 2019-07-11 | 2019-07-11 | Application of the TARS as the molecular marker of diagnosis Male Osteoporosis |
| CN201911029476.7A Active CN110564845B (en) | 2019-07-11 | 2019-10-28 | Application of TARS (total amyloid receptor) as molecular marker for diagnosing male osteoporosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911029476.7A Active CN110564845B (en) | 2019-07-11 | 2019-10-28 | Application of TARS (total amyloid receptor) as molecular marker for diagnosing male osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN110317867A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110564845A (en) * | 2019-07-11 | 2019-12-13 | 德阳市人民医院 | Application of TARS (total amyloid receptor) as molecular marker for diagnosing male osteoporosis |
| CN110577995A (en) * | 2019-07-11 | 2019-12-17 | 德阳市人民医院 | Diagnostic marker for male osteoporosis |
| CN110577994A (en) * | 2019-07-11 | 2019-12-17 | 德阳市人民医院 | Product for non-invasive diagnosis of male osteoporosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6240500B2 (en) * | 2010-04-27 | 2017-11-29 | エータイアー ファーマ， インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of threonyl-tRNA synthetase |
| JP6046607B2 (en) * | 2010-05-27 | 2016-12-21 | エータイアー ファーマ， インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of glutaminyl tRNA synthetase |
| CN110317867A (en) * | 2019-07-11 | 2019-10-11 | 德阳市人民医院 | Application of the TARS as the molecular marker of diagnosis Male Osteoporosis |
-
2019
- 2019-07-11 CN CN201910626648.2A patent/CN110317867A/en active Pending
- 2019-10-28 CN CN201911029476.7A patent/CN110564845B/en active Active
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110564845A (en) * | 2019-07-11 | 2019-12-13 | 德阳市人民医院 | Application of TARS (total amyloid receptor) as molecular marker for diagnosing male osteoporosis |
| CN110577995A (en) * | 2019-07-11 | 2019-12-17 | 德阳市人民医院 | Diagnostic marker for male osteoporosis |
| CN110577994A (en) * | 2019-07-11 | 2019-12-17 | 德阳市人民医院 | Product for non-invasive diagnosis of male osteoporosis |
| CN110577994B (en) * | 2019-07-11 | 2020-09-01 | 德阳市人民医院 | Product for non-invasive diagnosis of male osteoporosis |
| CN110577995B (en) * | 2019-07-11 | 2020-11-06 | 德阳市人民医院 | Diagnostic marker for male osteoporosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110564845A (en) | 2019-12-13 |
| CN110564845B (en) | 2020-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110317867A (en) | Application of the TARS as the molecular marker of diagnosis Male Osteoporosis | |
| CN108504658A (en) | Purposes of the LINC01836 in preparing diagnosing gastric cancer product, medicine | |
| CN110241208A (en) | Application of the TREM2 as the molecular marker of early diagnosis coronary heart disease | |
| CN105132575A (en) | Molecular marker for osteoporosis and application of marker | |
| He et al. | Increasing fracture risk associates with plasma circulating microRNAs in aging people’s sarcopenia | |
| CN107312865A (en) | Purposes of the LOC100130111 in osteosarcoma diagnostic products, medicine is prepared | |
| CN110093416A (en) | Application of the biomarker in diagnosis orthopaedic disease | |
| US11124832B2 (en) | Serum miRNA marker for OPLL diagnosis and application thereof | |
| Ojamaa | Epidemiology of gynecological cancer in Estonia | |
| CN105132574A (en) | Marker for diagnosis and treatment of osteoarthritis and application of marker | |
| Iafolla et al. | Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P) | |
| JP2011109929A (en) | METHOD FOR PREDICTING MEDICINAL EFFECT OF HUMAN TYPE ANTI-TNFalpha ANTIBODY MEDICINE ON RHEUMATOID ARTHRITIS AND APPARATUS FOR PREDICTING MEDICINAL EFFECT | |
| CN108929903A (en) | Marker and kit for chronic periodontitis screening, diagnosis, therapeutic evaluation | |
| CN110229891A (en) | The product of non-invasive diagnosis Male Osteoporosis | |
| Yee et al. | Sarcopenia in women with hip fracture: A comparison of hormonal biomarkers and their relationship to skeletal muscle mass and function | |
| CN107287310A (en) | A kind of colorectal cancer auxiliary diagnosis and/or Index for diagnosis kit and application based on SPEXIN | |
| CN105950714B (en) | It is a kind of diagnose osteoarthritis product and its application | |
| CN110229892A (en) | TYW3 as Male Osteoporosis diagnosis | |
| Wang et al. | Evaluating the effect of methotrexate on the rate of renal fibrosis by elastography and fibrosis-related gene expression | |
| CN109182514A (en) | Pulmonary cancer diagnosis or transfer diagnosis marker LncRNA Loc729658 and kit and its application | |
| CN108004318A (en) | The combination of serum miRNA marker and its application for early-stage breast cancer examination | |
| CN117286266B (en) | Microbial marker for bile duct cancer diagnosis or prognosis evaluation and application thereof | |
| CN110038116A (en) | The purposes of people hepatic secretion Protein G PNMB or its antagonist or agonist | |
| Arons et al. | Tumor Genomics and the Association with Survival in Recurrent/metastatic Head and Neck Cancer Patients | |
| Russial et al. | Clinical Utility of Pre-Treatment and Surveillance Circulating Tumor Tissue Modified Viral HPV DNA to Detect Recurrence in a Community Based HN Cancer Program |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191011 |